SCHEMBL3606183

SCHEMBL3606183

Cc1ccc(NC(=O)Nc2ccc(F)c(F)c2)cc1Nc1ccc2c(c1)NC(=O)/C2=C\c1ccc[nH]1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 11/20 0.80
KIT P10721 7/20 0.80
NTRK1 P04629 4/20 0.80
PDGFRB P09619 3/20 0.80
NTRK3 Q16288 3/20 0.80
CSF1R P07333 2/20 0.80
JAK2 O60674 1/20 0.80
ABL1 P00519 1/20 0.80
INSR P06213 1/20 0.80
LYN P07948 1/20 0.80
RET P07949 1/20 0.80
IGF1R P08069 1/20 0.80
MET P08581 1/20 0.80
ROS1 P08922 1/20 0.80
FGR P09769 1/20 0.80
SRC P12931 1/20 0.80
FLT1 P17948 1/20 0.80
FGFR4 P22455 1/20 0.80
FGFR3 P22607 1/20 0.80
EPHA3 P29320 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3606185 1.00 FLT3 (0.80) FLT3KITNTRK1PDGFRBNTRK3
SCHEMBL13256137 0.95 FLT3 (0.80) FLT3KITNTRK1PDGFRBNTRK3
SCHEMBL13256136 0.94 FLT3 (0.76) FLT3KITNTRK1PDGFRBNTRK3
SCHEMBL13256135 0.93 FLT3 (0.80) FLT3KITNTRK1PDGFRBNTRK3
SCHEMBL3609028 0.93 FLT3 (0.77) FLT3KITNTRK1PDGFRBNTRK3
SCHEMBL3609029 0.93 FLT3 (0.77) FLT3KITNTRK1PDGFRBNTRK3
SCHEMBL3610575 0.92 NTRK1 (0.78) FLT3KITNTRK1PDGFRBNTRK3
SCHEMBL3606425 0.92 FLT3 (0.81) FLT3KITNTRK1PDGFRBNTRK3
SCHEMBL3610573 0.92 NTRK1 (0.78) FLT3KITNTRK1PDGFRBNTRK3
SCHEMBL3606422 0.92 FLT3 (0.81) FLT3KITNTRK1PDGFRBNTRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100168182-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-07-01 US claimed
EP-2102190-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2009-09-23 EP claimed
WO-2008073480-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2008-06-19 WO claimed
US-20100168182-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-07-01 US disclosed
US-20100168182-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-07-01 US disclosed
US-20100168182-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168182-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS NTRK2, PDGFRB, PDGFRA FLT3 127/4885KIT 9/4885NTRK1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.